Compare Albemarle Corp. (ALB) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Boston Scientific Corporation — how do they compare? Albemarle Corp. trades at $129.64 (market cap $15.27B), while Boston Scientific Corporation trades at $50.95 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 4.9× Albemarle Corp.'s market cap, and Albemarle Corp. pays a 1.27% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| ALB | BSX | |
|---|---|---|
Market Cap | $15.27B | $74.19B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $108.14 |
52-Week Low | $72.58 | $42.63 |
Enterprise Value | $17.75B | $86.27B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $131.21, up 0.08% on the day, showing a bullish technical trend with strong support at $129 and resistance at $133. The company reported robust Q2 2026 results, beating EPS estimates with $3.75 versus $3.20 expected, driven by improved lithium pricing and specialties growth. However, net income remains negative for 2025 at -$510.63M, and the P/E ratio is elevated at 479.11, indicating high valuation expectations. Analyst sentiment is mixed with a consensus price target of $184.50 but only 42% buy ratings.
Outlook: ALB benefits from strong lithium demand and cost controls, but faces risks from volatile lithium prices and sequential margin pressure in Q3. The stock offers growth potential if execution continues, yet high valuation and earnings inconsistency warrant caution. Near-term price action hinges on Q3 results and lithium market trends.
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
